Generic Medicine Info
Known hypersensitivity to gatifloxacin, other quinolones.
Special Precautions
Medication should not to be introduced into the anterior chamber of the eye. Pregnancy and lactation. Patient Counselling Contact lenses should not be worn during treatment. Avoid contamination of the applicator tip w/ material from the eye, fingers or other sources. Monitoring Parameters Monitor signs of infection. Slit-lamp biomicroscopy and fluorescein staining may be necessary for careful monitoring.
Adverse Reactions
Conjunctival irritation, increased lacrimation, keratitis, papillary conjunctivitis, chemosis, conjunctival haemorrhage, ocular dryness and redness, ocular discharge/irritation/pain, eyelid oedema, headache, reduced visual acuity, and taste disturbance.
Potentially Fatal: Hypersensitivity reactions including anaphylaxis; fungal or bacterial superinfection.
Drug Interactions
Additive effect w/ drugs that prolong QT interval e.g. antiarrhythmic agents (amiodarone, quinidine, sotalol), arsenic trioxide, cisapride, chlorpromazine, droperidol, mefloquine, dolasetron, mesoridazine, moxifloxacin, pimozide, tacrolimus, pentamidine, thioridazine, ziprasidone. Increased risk of blood glucose disturbances w/ drugs that alter blood glucose concentrations (e.g. antidiabetics). Systemic admin may elevate plasma concentrations of theophylline, interfere caffeine metabolism, enhance effects of oral anticoagulant (warfarin and its derivatives), and transient elevations in serum creatinine w/ ciclosporin.
CIMS Class
Eye Anti-Infectives & Antiseptics / Quinolones
ATC Classification
J01MA16 - gatifloxacin ; Belongs to the class of fluoroquinolones. Used in the systemic treatment of infections.
S01AE06 - gatifloxacin ; Belongs to the class of quinolone antiinfectives. Used in the treatment of eye infections.
Disclaimer: This information is independently developed by CIMS based on gatifloxacin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in